ANT-EGFR SINGLE-STRANDED FV AND ANTI-EGFR ANTIBODY

• Main Authors: BENDIG MARY M, ROSELL ELISABET, KETTLEBOROUGH A CATHRINE, ADAN JAUME, PIULATS JAUME, MITJANS FRANCESC, BLASCO FRANCESC, GUESSOW DETLEF, ANSELL KEITH H
• Format: Patent
• Language: English
• Published: 02.02.2006
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide new anti-EGFR antibodies and single-stranded Fvs (scFvs) thereof which can be obtained from phage-antibody libraries constructed from cells of an immunized mammalian, preferably a mouse. SOLUTION: Two of the single-stranded Fvs isolated from the phage-antibody libraries are genetically engineered to create partially humanized whole antibody molecules. These chimeric anti-EGFR antibodies contain constant regions of human immunoglobulins, and can be used as well as the single-stranded Fvs as agents for the diagnosis and therapy of human tumors. COPYRIGHT: (C)2006,JPO&NCIPI